@article{oai:air.repo.nii.ac.jp:00003227,
 author = {AJIMINE, Takuma and OHSHIMA, Shigetoshi and GOTO, Takashi and KOMATSU, Masafumi and NAKANE, Kunio and YAGISAWA, Hitoshi and Goto, Mitsuo and NAKAJIMA, Kou and Miura, Masato and FUNAOKA, Masato and HOSHINO, Takao and KURAMITSU, Tomoyuki and FUJISHIMA, Yuukou and WATANABE, Daisuke and Segawa, Daisuke and Inomata, Masaaki and IIJIMA, Katsunori},
 issue = {3/4},
 journal = {秋田医学, AKITA JOURNAL OF MEDICINE},
 month = {Mar},
 note = {AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for HCV genotype 1.
METHOD : The study population was 253 patients who were enrolled in the Akita hepatitis C study group from 2015 to 2016.　We followed them until 24 weeks after the end of treatment.
RESULT : The sustained virological response (SVR) at 24 weeks after the end of treatment rates were 84.2%.　In univariate analyses, the Y93 mutation and a history of triple therapy with protease inhibitor reduced the SVR 24 rate.　In multivariate analyses, the Y93H mutation, a history of triple therapy with protease inhibitor, and LC status reduced the SVR 24 rate.　The most frequently reported adverse event was ALT elevation, noted in 25.7% of patients.　10.7% of patients had T-Bil elevation, 7.1% experienced drug rush, 11.5% experienced respiratory symptoms, 10.3% developed a fever, and 7.1% experienced digestive symptom.　Only 9 (3.6%) patients stopped taking the drugs due to drug-related severe adverse events.
CONCLUSION : DCV and ASV therapy showed a high efficacy and low rate of adverse events.},
 pages = {101--109},
 title = {EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1},
 volume = {44},
 year = {2018}
}